- Isatuximab for the treatment of relapsed/refractory multiple myeloma2020 | 1. lékařská fakulta
- A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab2021 | 1. lékařská fakulta
- Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA2022 | 1. lékařská fakulta
- Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis2022 | 1. lékařská fakulta
- Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study2023 | 1. lékařská fakulta
- Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis2021 | Lékařská fakulta v Hradci Králové
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis2022 | 1. lékařská fakulta
- Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA2022 | 1. lékařská fakulta
- Můžeme myelom zcela vyléčit? Daratumumab, elotuzumab a isatuximab v léčbě mnohočetného myelomu2023 | 1. lékařská fakulta
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial2021 | 1. lékařská fakulta
- Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma2021 | 1. lékařská fakulta
- Novinky v léčbě mnohočetného myelomu v roce 20172018 | 1. lékařská fakulta
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study2019 | 1. lékařská fakulta
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study2022 | 1. lékařská fakulta
- Komentář ke studii2020 | 1. lékařská fakulta
- Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes2022 | 1. lékařská fakulta
- Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies2021 | 1. lékařská fakulta
- Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma2021 | Lékařská fakulta v Hradci Králové
- Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy2022 | 1. lékařská fakulta, Lékařská fakulta v Hradci Králové, 3. lékařská fakulta